HR23B, a biomarker for HDAC inhibitors
<p>As our understanding of cancer biology increases and novel therapies are developed, an increasing number of predictive biomarkers are becoming clinically available. Aberrant acetylation has been strongly linked to tumourigenesis and the modulation of acetylation through targeting histone d...
第一著者: | Khan, OA |
---|---|
その他の著者: | La Thangue, NB |
フォーマット: | 学位論文 |
言語: | English |
出版事項: |
2013
|
主題: |
類似資料
-
Mitochondrial modulators of hypoxia-related pathways in tumours
著者:: Snell, CE
出版事項: (2013) -
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
著者:: New, M
出版事項: (2014) -
Angiogenesis in human lung tumours
著者:: Ferguson, ML
出版事項: (2008) -
Risk factors for haemorrhage in patients with haematological malignancies
著者:: Estcourt, LJ
出版事項: (2014) -
Regulation of stemness and differentiation in colorectal cancer
著者:: Gandhi, S
出版事項: (2010)